Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.


Clinical Trial Description

In this phase II trial, patients with stage IV melanoma will be treated with dacarbazine and carmustine commonly used in this cancer, but given using a schedule that might theoretically improve on this combination. Patients on this study will be assessed in terms of toxicity, response rate, median duration of response, median time to disease progression, and median survival. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01692691
Study type Interventional
Source Western Regional Medical Center
Contact
Status Terminated
Phase Phase 2
Start date August 2012
Completion date October 2014

See also
  Status Clinical Trial Phase
Terminated NCT01702896 - Interleukin-2 in Metastatic Melanoma Phase 2
Active, not recruiting NCT03514901 - To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. Phase 2
Active, not recruiting NCT03913923 - Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma Phase 2
Completed NCT03879395 - Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study
Recruiting NCT05732805 - A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma Phase 3